Table 4.
Univariate and Multivariate Analysis for the Risk Factors of HCC Based on Variables at 2 Years after ETV Commencement
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age, yr | 1.056 (1.031–1.082) | <0.001 | 1.046 (1.022–1.072) | <0.001 | |
| Male sex | 1.325 (0.825–2.127) | 0.197 | |||
| AST, IU/L | 1.018 (1.005–1.030) | 0.005 | 1.006 (0.989–1.023) | 0.507 | |
| ALT, IU/L | 1.001 (0.988–1.014) | 0.899 | |||
| Albumin, g/dL | 0.463 (0.301–0.713) | <0.001 | 1.016 (0.556–1.856) | 0.978 | |
| Total bilirubin, mg/dL | 1.109 (0.940–1.309) | 0.220 | |||
| Platelet counts, ×103/μL | 0.993 (0.987–0.998) | 0.010 | 0.997 (0.990–1.005) | 0.535 | |
| Partial virological response | 2.536 (1.423–4.520) | 0.002 | 2.358 (1.310–4.245) | 0.004 | |
| CP class | |||||
| A | Reference | ||||
| B | 1.422 (0.683–2.960) | 0.347 | |||
| C | 1.684 (0.233–12.145) | 0.605 | |||
| MELD | 0.992 (0.938–1.050) | 0.791 | |||
| APRI | 1.160 (0.990–1.358) | 0.066 | 0.958 (0.751–1.223) | 0.732 | |
| FIB-4 index | 1.141 (1.080–1.206) | <0.001 | 1.103 (1.035–1.177) | 0.003 | |
| FIB-4 ≥3.25 | 2.868 (1.804–4.558) | <0.001 | 2.243 (1.391–3.616) | 0.001 | |
HCC, hepatocellular carcinoma; ETV, entecavir; HR, hazard ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CP, Child-Pugh; MELD, Model for End-Stage Liver Disease; APRI, aspartate transaminase to platelet ratio index.